Cost Effectiveness Analysis of Nilotinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia from the Health Insurance Perspective in Egypt
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.2225
https://www.valueinhealthjournal.com/article/S1098-3015(16)33591-4/fulltext
Title :
Cost Effectiveness Analysis of Nilotinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia from the Health Insurance Perspective in Egypt
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33591-4&doi=10.1016/j.jval.2016.09.2225
First page :
A735
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2110